by Qingyang Li | Jul 29, 2022 | The Heart Act
The purpose of the HEART Act S. 4348 is to support and improve the review of drugs to treat rare diseases and conditions. Learn more about it...
by Qingyang Li | Mar 6, 2022 | CURE!
ARO-APOC3 is an investigational therapeutic being evaluated by Arrowhead Pharmaceuticals, Inc. forthe treatment of FCS. A Phase 3 clinical trial, the AROAPOC3-3001 Palisade Study is currently recruitingadults with a clinical diagnosis of FCS at multiple research...
by Qingyang Li | Dec 2, 2020 | FCS News
During the latest FCS patient-caregiver virtual meeting (link) hosted by the FCS Foundation, Ionis introduced the BALANCE study to the meeting attendance. Today, Ionis officially announced the initiation of the global Phase 3 BALANCE study via a press release (link)....
by Qingyang Li | Jul 19, 2020 | FCS News
CNN interviewed FCS Foundation’s co-presidents Melissa and Lindsey about the #TheHeartAct2020. It was an honor to share our journey with them. The FCS community is so proud to support this legislation and work alongside so many #raredisease groups, including the...
Recent Comments